Mauna Kea Technologies and Tasly Pharmaceutical Announce Joint Venture in China

Tasly Mauna Kea Medical Engineering Technology Co. Ltd will accelerate the development of the Cellvizio market in China and launch a dedicated platform for neurosurgical applications worldwide.

SHANGHAI, China, PARIS and BOSTON, November 7, 2022–(BUSINESS WIRE)–Regulatory news:

Mauna Kea Technologies (Euronext: MKEA, Mauna Kea) (Paris: MKEA) (OTCQX: MKEAY), inventor of Cellvizio®, an interdisciplinary platform for confocal laser miniprobe and needle endomicroscopy (p/nCLE), and Tasly Pharmaceutical Group (SH Exchange: 600535, “Tasly”), announced today that they have taken another key step in their strategic partnership.

Tasly Mauna Kea Medical Engineering Technology Co. OOObased in the Chinese province of Zhejiang, whose registered capital is 250 million yuan (35 million euros).one), is now legally constituted. Tasly Mauna Kea Medical Engineering Technology Co. Ltd. will serve as the exclusive commercial platform to expand Cellvizio’s presence in the Chinese domestic market and launch a dedicated platform for neurosurgical applications worldwide.

Dr. Jing Su, Managing Director of Tasly Pharmaceutical Group, commented: “We are very excited about our joint venture’s prospects in China and beyond, thanks to the significant resources that we are collectively putting into place. We look forward to the future success of this partnership built on the synergy between Mauna Kea’s Cellvizio platform, Tasly’s commercial strength and expertise in pharmaceutical development.. »

Sasha Loiseau, PhD, Chairman and CEO of Mauna Kea Technologies, concluded: “We are taking a key step in our partnership with Tasly that will enable us to realize our shared commercial ambitions. I am very pleased with Cellvizio’s track record in China and the opportunity to benefit from Tasly’s extensive sales network in this key market. »

About the pharmaceutical group “Tasly”

Adhering to the company’s mission of “sharing the joy of health with everyone”, Tasly has always promoted the integrated development of traditional Chinese medicine (TCM) and modern medicine. Tasly constantly focuses on three therapeutic areas: cardiovascular diseases, digestive and metabolic diseases, and tumors, which have the largest market share and are developing rapidly in China. The company is committed to conducting research and development in the field of medicines requiring clinical emergency and satisfying the unmet needs of the Chinese clinical market. Relying on the advantages of the coordinated development of modern TCM, biological medicine and chemical medicine, it establishes a strategy for innovative drugs and continues to maintain its leading position in the industry and the impetus for the development of R&D and innovation. For more information visit

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company that manufactures and markets Cellvizio®, a real-time in vivo cellular imaging platform. This technology provides unique in vivo cellular imaging that allows clinicians to track disease progression over time, assess responses as they occur, classify areas of uncertainty, and guide surgical interventions. The Cellvizio platform is used in many countries around the world and in several medical specialties and changes the way doctors diagnose and treat patients. For more information visit


This press release contains forward-looking statements regarding Mauna Kea Technologies and its business. All statements, other than statements of historical fact, included in this press release, including but not limited to statements about the financial condition, business, strategies, plans and management objectives of Mauna Kea Technologies with respect to future transactions, are forward-looking statements. Mauna Kea Technologies believes that these forward-looking statements are based on reasonable assumptions. However, no guarantee can be made as to whether the projections expressed in these forward-looking statements will be achieved, which are subject to numerous risks and uncertainties, including those described in Chapter 3 of the Mauna Kea Technologies 2021 Universal Registration Document filed with Autorité. des Marchés financiers (AMF) dated October 18, 2022 under the number D-22-0773 available on the Company’s website (, as well as the risks associated with changes in economic conditions, financial markets and markets managed by Mauna Kea Technologies. The forward-looking statements contained in this press release are also subject to risks unknown to Mauna Kea Technologies or which Mauna Kea Technologies does not consider material at this time. The realization of all or part of these risks could cause the actual results, financial conditions, performance or achievements of Mauna Kea Technologies to differ materially from the results, financial conditions, performance or achievements set forth in these forward-looking statements. This press release and the information contained therein does not constitute an offer to sell or subscribe to, nor an offer to buy or subscribe to Mauna Kea Technologies shares in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification in under the securities laws of such jurisdiction. In some jurisdictions, distribution of this press release may be restricted by local law. Persons into whose possession this document comes are responsible for compliance with all local regulations that apply to this document.

one From November 06, 2022

View original version on


Investor Relations
NewCap – Financial Communication
Thomas Grosjean
+33 (0)1 44 71 94 94
[email protected]

Tasly Pharmaceutical Group Press contacts
+86 22 26736290